PubMed:31072570
Annnotations
sonoma
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T-0 | 28-41 | NEGREG | denotes | Reversibility |
| T-1 | 45-53 | DISEASE | denotes | Fibrosis |
| T-2 | 81-94 | DISEASE | denotes | Heart Failure |
| T-3 | 121-129 | DISEASE | denotes | fibrosis |
| T-4 | 184-195 | REG | denotes | dysfunction |
| T-5 | 199-212 | DISEASE | denotes | heart failure |
| T-6 | 214-216 | DISEASE | denotes | HF |
| T-7 | 222-229 | REG | denotes | depends |
| T-8 | 233-243 | POSREG | denotes | activation |
| T-9 | 248-263 | CPA | denotes | differentiation |
| T-10 | 361-363 | DISEASE | denotes | HF |
| T-11 | 365-373 | DISEASE | denotes | fibrosis |
| T-12 | 445-460 | CPA | denotes | differentiation |
| T-13 | 491-493 | DISEASE | denotes | HF |
| T-14 | 1046-1054 | DISEASE | denotes | fibrosis |
| T-15 | 1073-1081 | GENE | denotes | collagen |
| T-16 | 1085-1094 | POSREG | denotes | prominent |
| T-17 | 1098-1100 | DISEASE | denotes | HF |
| T-18 | 1151-1157 | MPA | denotes | levels |
| T-19 | 1174-1196 | GENE | denotes | growth factor (TGF)-β1 |
| T-20 | 1198-1211 | GENE | denotes | lysyl oxidase |
| T-21 | 1213-1222 | GENE | denotes | periostin |
| T-22 | 1228-1239 | GENE | denotes | osteopontin |
| T-23 | 1244-1252 | POSREG | denotes | elevated |
| T-24 | 1287-1289 | DISEASE | denotes | HF |
| T-25 | 1406-1408 | DISEASE | denotes | HF |
| T-26 | 1423-1427 | POSREG | denotes | high |
| T-27 | 1450-1459 | GENE | denotes | cytokines |
| T-28 | 1468-1482 | PATHWAY | denotes | TGF-β1 pathway |
| T-29 | 1486-1495 | POSREG | denotes | activated |
| T-30 | 1497-1507 | NEGREG | denotes | Inhibition |
| T-31 | 1511-1517 | GENE | denotes | TGF-β1 |
| T-32 | 1537-1539 | DISEASE | denotes | HF |
| T-33 | 1546-1554 | POSREG | denotes | promotes |
| T-34 | 1555-1572 | CPA | denotes | dedifferentiation |
| T-35 | 1587-1591 | NEGREG | denotes | loss |
| T-36 | 1611-1616 | GENE | denotes | actin |
| T-37 | 1621-1654 | MPA | denotes | depolymerization of stress fibers |
| T-38 | 1660-1667 | NEGREG | denotes | reduces |
| T-39 | 1672-1682 | MPA | denotes | expression |
| T-40 | 1774-1776 | DISEASE | denotes | HF |
| T-41 | 1784-1792 | REG | denotes | variable |
| T-42 | 1803-1818 | CPA | denotes | differentiation |
| T-43 | 1823-1829 | POSREG | denotes | retain |
| T-44 | 1858-1862 | NEGREG | denotes | less |
| R-6 | T-3 | T-7 | ThemeOf | fibrosis,depends |
| R-7 | T-9 | T-7 | ThemeOf | differentiation,depends |
| R-8 | T-8 | T-7 | ThemeOf | activation,depends |
| R-9 | T-13 | T-12 | ThemeOf | HF,differentiation |
| R-10 | T-14 | T-16 | ThemeOf | fibrosis,prominent |
| R-11 | T-16 | T-17 | CauseOf | prominent,HF |
| R-12 | T-19 | T-18 | ThemeOf | growth factor (TGF)-β1,levels |
| R-13 | T-19 | T-23 | ThemeOf | growth factor (TGF)-β1,elevated |
| R-14 | T-18 | T-23 | ThemeOf | levels,elevated |
| R-15 | T-20 | T-23 | ThemeOf | lysyl oxidase,elevated |
| R-16 | T-20 | T-18 | ThemeOf | lysyl oxidase,levels |
| R-17 | T-21 | T-23 | ThemeOf | periostin,elevated |
| R-18 | T-21 | T-18 | ThemeOf | periostin,levels |
| R-19 | T-22 | T-23 | ThemeOf | osteopontin,elevated |
| R-0 | T-1 | T-0 | ThemeOf | Fibrosis,Reversibility |
| R-1 | T-2 | T-1 | ThemeOf | Heart Failure,Fibrosis |
| R-2 | T-5 | T-4 | ThemeOf | heart failure,dysfunction |
| R-3 | T-6 | T-4 | ThemeOf | HF,dysfunction |
| R-4 | T-3 | T-5 | CauseOf | fibrosis,heart failure |
| R-5 | T-3 | T-6 | CauseOf | fibrosis,HF |
| R-20 | T-22 | T-18 | ThemeOf | osteopontin,levels |
| R-21 | T-28 | T-29 | ThemeOf | TGF-β1 pathway,activated |
| R-22 | T-30 | T-38 | CauseOf | Inhibition,reduces |
| R-23 | T-39 | T-38 | ThemeOf | expression,reduces |
| R-24 | T-41 | T-43 | CauseOf | variable,retain |
| R-25 | T-42 | T-41 | ThemeOf | differentiation,variable |
sonoma2
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T0 | 0-23 | CPA | denotes | Myofibroblast Phenotype |
| T1 | 28-41 | REG | denotes | Reversibility |
| T2 | 45-53 | DISEASE | denotes | Fibrosis |
| T3 | 71-94 | DISEASE | denotes | End-Stage Heart Failure |
| T4 | 108-129 | DISEASE | denotes | Interstitial fibrosis |
| T5 | 120-128 | DISEASE | denotes | fibrosi |
| T6 | 183-211 | DISEASE | denotes | dysfunction in heart failur |
| T7 | 184-195 | REG | denotes | dysfunction |
| T8 | 199-212 | DISEASE | denotes | heart failure |
| T9 | 214-216 | DISEASE | denotes | HF |
| T10 | 222-229 | REG | denotes | depends |
| T11 | 233-243 | POSREG | denotes | activation |
| T12 | 248-263 | CPA | denotes | differentiation |
| T13 | 361-363 | DISEASE | denotes | HF |
| T14 | 364-372 | DISEASE | denotes | fibrosi |
| T15 | 365-373 | DISEASE | denotes | fibrosis |
| T16 | 381-391 | REG | denotes | reversible |
| T17 | 445-460 | CPA | denotes | differentiation |
| T18 | 481-493 | DISEASE | denotes | end-stage HF |
| T19 | 533-546 | REG | denotes | reversibility |
| T20 | 654-662 | DISEASE | denotes | s (ische |
| T21 | 667-689 | DISEASE | denotes | nd dilated cardiomyopa |
| T22 | 670-692 | DISEASE | denotes | dilated cardiomyopathy |
| T23 | 1033-1054 | DISEASE | denotes | Interstitial fibrosis |
| T24 | 1042-1050 | DISEASE | denotes | ial fibr |
| T25 | 1060-1072 | REG | denotes | cross-linked |
| T26 | 1073-1081 | GENE | denotes | collagen |
| T27 | 1085-1094 | POSREG | denotes | prominent |
| T28 | 1098-1100 | DISEASE | denotes | HF |
| T29 | 1126-1135 | POSREG | denotes | activated |
| T30 | 1151-1157 | MPA | denotes | levels |
| T31 | 1157-1195 | GENE | denotes | of transforming growth factor (TGF)-β |
| T32 | 1161-1196 | GENE | denotes | transforming growth factor (TGF)-β1 |
| T33 | 1198-1211 | GENE | denotes | lysyl oxidase |
| T34 | 1212-1221 | GENE | denotes | periosti |
| T35 | 1213-1222 | GENE | denotes | periostin |
| T36 | 1227-1238 | GENE | denotes | osteoponti |
| T37 | 1228-1239 | GENE | denotes | osteopontin |
| T38 | 1244-1252 | POSREG | denotes | elevated |
| T39 | 1287-1289 | DISEASE | denotes | HF |
| T40 | 1362-1368 | NEGREG | denotes | mature |
| T41 | 1369-1377 | GENE | denotes | α-smooth |
| T42 | 1406-1408 | DISEASE | denotes | HF |
| T43 | 1423-1427 | POSREG | denotes | high |
| T44 | 1428-1434 | MPA | denotes | levels |
| T45 | 1438-1459 | GENE | denotes | profibrotic cytokines |
| T46 | 1468-1474 | GENE | denotes | TGF-β1 |
| T47 | 1471-1480 | GENE | denotes | -β1 pathw |
| T48 | 1486-1495 | POSREG | denotes | activated |
| T49 | 1497-1507 | NEGREG | denotes | Inhibition |
| T50 | 1511-1517 | GENE | denotes | TGF-β1 |
| T51 | 1517-1526 | GENE | denotes | receptor |
| T52 | 1537-1539 | DISEASE | denotes | HF |
| T53 | 1546-1554 | POSREG | denotes | promotes |
| T54 | 1555-1572 | CPA | denotes | dedifferentiation |
| T55 | 1587-1591 | NEGREG | denotes | loss |
| T56 | 1595-1616 | GENE | denotes | α-smooth muscle actin |
| T57 | 1621-1654 | MPA | denotes | depolymerization of stress fibers |
| T58 | 1660-1667 | NEGREG | denotes | reduces |
| T59 | 1672-1682 | MPA | denotes | expression |
| T60 | 1686-1697 | GENE | denotes | profibrotic |
| T61 | 1708-1724 | MPA | denotes | cytokines levels |
| T62 | 1764-1776 | DISEASE | denotes | end-stage HF |
| T63 | 1784-1792 | REG | denotes | variable |
| T64 | 1803-1818 | CPA | denotes | differentiation |
| T65 | 1823-1829 | POSREG | denotes | retain |
| T66 | 1858-1862 | NEGREG | denotes | less |
| T67 | 1920-1940 | DISEASE | denotes | antifibrotic therapy |
| R8 | T11 | T7 | CauseOf | activation,dysfunction |
| R9 | T11 | T10 | ThemeOf | activation,depends |
| R10 | T12 | T10 | ThemeOf | differentiation,depends |
| R11 | T13 | T16 | ThemeOf | HF,reversible |
| R12 | T15 | T16 | ThemeOf | fibrosis,reversible |
| R13 | T18 | T17 | ThemeOf | end-stage HF,differentiation |
| R14 | T18 | T19 | ThemeOf | end-stage HF,reversibility |
| R15 | T23 | T25 | ThemeOf | Interstitial fibrosis,cross-linked |
| R0 | T2 | T1 | ThemeOf | Fibrosis,Reversibility |
| R1 | T3 | T1 | ThemeOf | End-Stage Heart Failure,Reversibility |
| R2 | T4 | T10 | ThemeOf | Interstitial fibrosis,depends |
| R3 | T7 | T10 | ThemeOf | dysfunction,depends |
| R4 | T8 | T7 | ThemeOf | heart failure,dysfunction |
| R5 | T8 | T10 | ThemeOf | heart failure,depends |
| R6 | T9 | T7 | ThemeOf | HF,dysfunction |
| R7 | T9 | T10 | ThemeOf | HF,depends |
| R16 | T23 | T27 | ThemeOf | Interstitial fibrosis,prominent |
| R17 | T26 | T27 | ThemeOf | collagen,prominent |
| R18 | T28 | T25 | ThemeOf | HF,cross-linked |
| R19 | T28 | T27 | ThemeOf | HF,prominent |
| R20 | T28 | T38 | ThemeOf | HF,elevated |
| R21 | T30 | T38 | ThemeOf | levels,elevated |
| R22 | T32 | T30 | ThemeOf | transforming growth factor (TGF)-β1,levels |
| R23 | T32 | T38 | ThemeOf | transforming growth factor (TGF)-β1,elevated |
| R24 | T33 | T30 | ThemeOf | lysyl oxidase,levels |
| R25 | T33 | T38 | ThemeOf | lysyl oxidase,elevated |
| R26 | T35 | T30 | ThemeOf | periostin,levels |
| R27 | T35 | T38 | ThemeOf | periostin,elevated |
| R28 | T37 | T30 | ThemeOf | osteopontin,levels |
| R29 | T37 | T38 | ThemeOf | osteopontin,elevated |
| R30 | T42 | T43 | ThemeOf | HF,high |
| R31 | T42 | T44 | ThemeOf | HF,levels |
| R32 | T42 | T48 | ThemeOf | HF,activated |
| R33 | T44 | T43 | ThemeOf | levels,high |
| R34 | T45 | T44 | ThemeOf | profibrotic cytokines,levels |
| R35 | T44 | T48 | ThemeOf | levels,activated |
| R36 | T45 | T43 | ThemeOf | profibrotic cytokines,high |
| R37 | T45 | T48 | ThemeOf | profibrotic cytokines,activated |
| R38 | T46 | T44 | ThemeOf | TGF-β1,levels |
| R39 | T46 | T48 | ThemeOf | TGF-β1,activated |
| R40 | T52 | T49 | ThemeOf | HF,Inhibition |
| R41 | T49 | T53 | CauseOf | Inhibition,promotes |
| R42 | T49 | T54 | CauseOf | Inhibition,dedifferentiation |
| R43 | T49 | T55 | CauseOf | Inhibition,loss |
| R44 | T49 | T58 | CauseOf | Inhibition,reduces |
| R45 | T50 | T49 | ThemeOf | TGF-β1,Inhibition |
| R46 | T52 | T53 | ThemeOf | HF,promotes |
| R47 | T54 | T53 | ThemeOf | dedifferentiation,promotes |
| R48 | T56 | T55 | ThemeOf | α-smooth muscle actin,loss |
| R49 | T57 | T55 | ThemeOf | depolymerization of stress fibers,loss |
| R50 | T59 | T58 | ThemeOf | expression,reduces |
| R51 | T60 | T59 | ThemeOf | profibrotic,expression |
| R52 | T61 | T59 | ThemeOf | cytokines levels,expression |
| R53 | T61 | T58 | ThemeOf | cytokines levels,reduces |
| R54 | T62 | T63 | ThemeOf | end-stage HF,variable |
| R55 | T62 | T64 | ThemeOf | end-stage HF,differentiation |
| R56 | T62 | T65 | ThemeOf | end-stage HF,retain |
| R57 | T63 | T65 | CauseOf | variable,retain |
| R58 | T64 | T63 | ThemeOf | differentiation,variable |
Inflammaging
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-95 | Sentence | denotes | Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure. |
| T2 | 96-107 | Sentence | denotes | BACKGROUND: |
| T3 | 108-307 | Sentence | denotes | Interstitial fibrosis is an important component of diastolic, and systolic, dysfunction in heart failure (HF) and depends on activation and differentiation of fibroblasts into myofibroblasts (MyoFb). |
| T4 | 308-392 | Sentence | denotes | Recent clinical evidence suggests that in late-stage HF, fibrosis is not reversible. |
| T5 | 393-404 | Sentence | denotes | OBJECTIVES: |
| T6 | 405-547 | Sentence | denotes | The study aims to examine the degree of differentiation of cardiac MyoFb in end-stage HF and the potential for their phenotypic reversibility. |
| T7 | 548-556 | Sentence | denotes | METHODS: |
| T8 | 557-725 | Sentence | denotes | Fibroblasts were isolated from the left ventricle of the explanted hearts of transplant recipients (ischemic and dilated cardiomyopathy), and from nonused donor hearts. |
| T9 | 726-819 | Sentence | denotes | Fibroblasts were maintained in culture without passaging for 4 or 8 days (treatment studies). |
| T10 | 820-931 | Sentence | denotes | Phenotyping included functional testing, immunostaining, and expression studies for markers of differentiation. |
| T11 | 932-1023 | Sentence | denotes | These data were complemented with immunohistology and expression studies in tissue samples. |
| T12 | 1024-1032 | Sentence | denotes | RESULTS: |
| T13 | 1033-1143 | Sentence | denotes | Interstitial fibrosis with cross-linked collagen is prominent in HF hearts, with presence of activated MyoFbs. |
| T14 | 1144-1253 | Sentence | denotes | Tissue levels of transforming growth factor (TGF)-β1, lysyl oxidase, periostin, and osteopontin are elevated. |
| T15 | 1254-1405 | Sentence | denotes | Fibroblastic cells isolated from HF hearts are predominantly MyoFb, proliferative or nonproliferative, with mature α-smooth muscle actin stress fibers. |
| T16 | 1406-1496 | Sentence | denotes | HF MyoFb express high levels of profibrotic cytokines and the TGF-β1 pathway is activated. |
| T17 | 1497-1742 | Sentence | denotes | Inhibition of TGF-β1 receptor kinase in HF MyoFb promotes dedifferentiation of MyoFb with loss of α-smooth muscle actin and depolymerization of stress fibers, and reduces the expression of profibrotic genes and cytokines levels to non-HF levels. |
| T18 | 1743-1754 | Sentence | denotes | CONCLUSION: |
| T19 | 1755-1957 | Sentence | denotes | MyoFb in end-stage HF have a variable degree of differentiation and retain the capacity to return to a less activated state, validating the potential for developing antifibrotic therapy targeting MyoFb. |
| T1 | 0-95 | Sentence | denotes | Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure. |
| T2 | 96-107 | Sentence | denotes | BACKGROUND: |
| T3 | 108-307 | Sentence | denotes | Interstitial fibrosis is an important component of diastolic, and systolic, dysfunction in heart failure (HF) and depends on activation and differentiation of fibroblasts into myofibroblasts (MyoFb). |
| T4 | 308-392 | Sentence | denotes | Recent clinical evidence suggests that in late-stage HF, fibrosis is not reversible. |
| T5 | 393-404 | Sentence | denotes | OBJECTIVES: |
| T6 | 405-547 | Sentence | denotes | The study aims to examine the degree of differentiation of cardiac MyoFb in end-stage HF and the potential for their phenotypic reversibility. |
| T7 | 548-556 | Sentence | denotes | METHODS: |
| T8 | 557-725 | Sentence | denotes | Fibroblasts were isolated from the left ventricle of the explanted hearts of transplant recipients (ischemic and dilated cardiomyopathy), and from nonused donor hearts. |
| T9 | 726-819 | Sentence | denotes | Fibroblasts were maintained in culture without passaging for 4 or 8 days (treatment studies). |
| T10 | 820-931 | Sentence | denotes | Phenotyping included functional testing, immunostaining, and expression studies for markers of differentiation. |
| T11 | 932-1023 | Sentence | denotes | These data were complemented with immunohistology and expression studies in tissue samples. |
| T12 | 1024-1032 | Sentence | denotes | RESULTS: |
| T13 | 1033-1143 | Sentence | denotes | Interstitial fibrosis with cross-linked collagen is prominent in HF hearts, with presence of activated MyoFbs. |
| T14 | 1144-1253 | Sentence | denotes | Tissue levels of transforming growth factor (TGF)-β1, lysyl oxidase, periostin, and osteopontin are elevated. |
| T15 | 1254-1405 | Sentence | denotes | Fibroblastic cells isolated from HF hearts are predominantly MyoFb, proliferative or nonproliferative, with mature α-smooth muscle actin stress fibers. |
| T16 | 1406-1496 | Sentence | denotes | HF MyoFb express high levels of profibrotic cytokines and the TGF-β1 pathway is activated. |
| T17 | 1497-1742 | Sentence | denotes | Inhibition of TGF-β1 receptor kinase in HF MyoFb promotes dedifferentiation of MyoFb with loss of α-smooth muscle actin and depolymerization of stress fibers, and reduces the expression of profibrotic genes and cytokines levels to non-HF levels. |
| T18 | 1743-1754 | Sentence | denotes | CONCLUSION: |
| T19 | 1755-1957 | Sentence | denotes | MyoFb in end-stage HF have a variable degree of differentiation and retain the capacity to return to a less activated state, validating the potential for developing antifibrotic therapy targeting MyoFb. |